Optimizing Biosimilar Implementation: A Framework for Access, Adoption, and Sustainability : Episode 2
Decision-Making and Evidence Evaluation of Biosimilars
A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study evidence, addressing stakeholder concerns through education, and implementing protocols to overcome barriers such as electronic health record integration and prior authorization challenges.
Video content above is prompted by the following:
- What characteristics (eg, cost, availability, accessibility, etc) of biosimilars are most important to your institution when deciding which agents to stock or keep on the formulary?
- What role do biosimilar switching studies play in this decision?
- In your experience, what are common barriers to implementing biosimilars at your institution?
- What strategies has your institution implemented to overcome the barriers to adopting biosimilars?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
